CLICK HERE TO BE CONTACTED

Nasdaq IPO

Speak With Soliton Before You Invest By Filling Out The Form Below

Interested in Investing? Please Fill out the Form Below the Video

Interested in Investing? Please Fill out the Form Below the Video

LEGAL DISCLAIMER: These videos contains forward-looking statements, typically identified by the use of such terms as “may,” “could,” “intend,” “anticipates,” “estimates,” “believes” or the negative of such terms and other comparable terminology. Forward-looking statements are based upon Soliton’s current plans, estimates, assumptions and beliefs that involve numerous risks and uncertainties, including, but not limited to, those set forth in the “Risk Factors” section of the offering statement set forth below. Actual results could vary materially from those set forth herein. These videos have been prepared by Soliton, Inc. for informational purposes and do not constitute an offer to sell or the solicitation of an offer to purchase securities. Any such offer will be made solely by means of the offering circular contained in the qualified offering statement. The information contained herein may not be used in connection with an offer of solicitation by anyone in any jurisdiction in which such offer or solicitation is not qualified or any person to whom it is unlawful to make such offer or solicitation. Soliton’s RAP device will need to receive clearance from the Food and Drug Administration, or FDA, in order to be marketed in the United States. Soliton expects to submit its filing for premarket clearance approval with the FDA in the second half of 2018. The RAP device is dependent upon regulatory approval and will be subject to ongoing regulatory review, and any failure to secure clearance or comply with continuing regulation by the FDA or other regulatory bodies could prevent the RAP device from entering the market. An offering circular that forms a part of the offering statement has been filed and qualified with the U.S. Securities and Exchange Commission. Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved or passed upon the accuracy or adequacy of these videos or of the offering circular.
Fix the following errors:
Hide